BeOne Medicines (ONC) Interest Expenses (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Interest Expenses of $32.9 million for Q1 2026, up 153.74% year-over-year from $13.0 million in Q1 2025, and up 59.84% quarter-over-quarter from $20.6 million in Q4 2025.
BeOne Medicines (ONC) Interest Expenses (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Interest Expenses for 12 consecutive years, with $32.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 153.74% year-over-year to $32.9 million; the TTM figure through Mar 2026 stood at $78.2 million (up 38.18% YoY), while the FY2025 annual figure was $3.6 billion, up 7.18% from the prior year.
- Interest Expenses grew to $32.9 million in Q1 2026 per ONC's latest filing, from $20.6 million in the prior quarter.
- Across five years, Interest Expenses topped out at $32.9 million in Q1 2026 and bottomed at $4.9 million in Q2 2023.
- Historically, Interest Expenses has averaged $11.9 million across 5 years, with a median of $12.1 million in 2023.
- Annual changes were most pronounced in 2022 — Interest Expenses declined 28.46% — and 2024, when it soared 170.56%.
- BeOne Medicines' Interest Expenses stood at $8.2 million in 2022, then jumped by 47.48% to $12.1 million in 2023, then jumped by 32.78% to $16.1 million in 2024, then grew by 28.15% to $20.6 million in 2025, then surged by 59.84% to $32.9 million in 2026.
- Business Quant data shows ONC's Interest Expenses at $32.9 million in Q1 2026, $20.6 million in Q4 2025, and $12.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 6.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.74 Mn |
| Jun 30, 2026 | 39.74 Mn |
| Mar 31, 2026 | 32.89 Mn |
| Mar 31, 2026 | 32.89 Mn |
| Dec 31, 2025 | 20.58 Mn |
| Dec 31, 2025 | 20.58 Mn |
| Sep 30, 2025 | 12.65 Mn |
| Sep 30, 2025 | 12.65 Mn |
| Jun 30, 2025 | 12.05 Mn |
| Jun 30, 2025 | 12.05 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Dec 31, 2024 | 16.06 Mn |
| Dec 31, 2024 | 16.06 Mn |
| Sep 30, 2024 | 14.31 Mn |
| Sep 30, 2024 | 14.31 Mn |
| Jun 30, 2024 | 13.23 Mn |
| Jun 30, 2024 | 13.23 Mn |
| Mar 31, 2024 | 12.40 Mn |
| Mar 31, 2024 | 12.40 Mn |